Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Bortezomib Patent Expiration

Bortezomib is Used for treating multiple myeloma patients who have not responded to previous therapies. It was first introduced by Takeda Pharmaceuticals Usa Inc in its drug Velcade on May 13, 2003. Another drug containing Bortezomib is Bortezomib. 21 different companies have introduced drugs containing Bortezomib.


Bortezomib Patents

Given below is the list of patents protecting Bortezomib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Bortezomib US11679119 Bortezomib compositions Sep 23, 2042 Maia Pharms Inc
Bortezomib US11752164 Bortezomib compositions Sep 23, 2042 Maia Pharms Inc
Bortezomib US12005069 Bortezomib compositions Sep 23, 2042 Maia Pharms Inc
Bortezomib US8962572 Bortezomib formulations Nov 03, 2032 Fresenius Kabi Usa
Velcade US5780454 Boronic ester and acid compounds May 03, 2017

(Expired)

 Takeda Pharms Usa
Velcade US5780454

(Pediatric)

 Boronic ester and acid compounds Nov 03, 2017

(Expired)

 Takeda Pharms Usa
Velcade US6083903 Boronic ester and acid compounds, synthesis and uses Oct 28, 2014

(Expired)

 Takeda Pharms Usa
Velcade US6297217 Boronic ester and acid compounds, synthesis and uses Oct 28, 2014

(Expired)

 Takeda Pharms Usa
Velcade US6617317 Boronic ester and acid compositions Oct 28, 2014

(Expired)

 Takeda Pharms Usa
Velcade US6713446 Formulation of boronic acid compounds Jan 25, 2022

(Expired)

 Takeda Pharms Usa
Velcade US6713446

(Pediatric)

 Formulation of boronic acid compounds Jul 25, 2022

(Expired)

 Takeda Pharms Usa
Velcade US6747150 Boronic ester and acid compounds, synthesis and uses Oct 28, 2014

(Expired)

 Takeda Pharms Usa
Velcade US6958319 Formulation of boronic acid compounds Jan 25, 2022

(Expired)

 Takeda Pharms Usa
Velcade US6958319

(Pediatric)

 Formulation of boronic acid compounds Jul 25, 2022

(Expired)

 Takeda Pharms Usa
Velcade US7119080 Boronic ester and acid compounds, synthesis and uses Oct 28, 2014

(Expired)

 Takeda Pharms Usa


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Bortezomib's patents.

Given below is the list recent legal activities going on the following patents of Bortezomib.

Event Date Patent/Publication
Patent litigations
Patent eGrant Notification 12 Sep, 2023 US11752164
Patent Issue Date Used in PTA Calculation 12 Sep, 2023 US11752164
Recordation of Patent eGrant 12 Sep, 2023 US11752164
Recordation of Patent Grant Mailed 12 Sep, 2023 US11752164
Mail Patent eGrant Notification 12 Sep, 2023 US11752164
Email Notification 12 Sep, 2023 US11752164
Email Notification 24 Aug, 2023 US11752164
Issue Notification Mailed 23 Aug, 2023 US11752164
Electronic Review 10 Aug, 2023 US11752164
Email Notification 10 Aug, 2023 US11752164



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Bortezomib Generics

Several generic applications have been filed for Bortezomib. The first generic version for Bortezomib was by Fresenius Kabi Usa Llc and was approved on May 2, 2022. And the latest generic version is by Hetero Labs Ltd Unit Vi and was approved on May 3, 2024.

Given below is the list of companies who have filed for Bortezomib generic.


1. PHARMASCIENCE INC

Pharmascience Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Pharmascience Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP May 2, 2022


2. NORVIUM BIOSCIENCE

Norvium Bioscience Llc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Discontinued INTRAVENOUS, SUBCUTANEOUS N/A Oct 31, 2022


3. MSN

Msn Laboratories Private Ltd has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Msn.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP Jul 26, 2022


4. EUGIA PHARMA

Eugia Pharma Specialities Ltd has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Eugia Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP May 2, 2022


5. HETERO LABS LTD VI

Hetero Labs Ltd Unit Vi has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Vi.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP May 3, 2024


6. APOTEX

Apotex Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP May 2, 2022


7. TEVA PHARMS USA

Teva Pharmaceuticals Usa Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Discontinued INTRAVENOUS, SUBCUTANEOUS N/A May 2, 2022


8. QILU PHARM HAINAN

Qilu Pharmaceutical Hainan Co Ltd has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Qilu Pharm Hainan.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP May 2, 2022


9. MEITHEAL

Meitheal Pharmaceuticals Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Meitheal.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP Jul 26, 2022


10. ZYDUS PHARMS

Zydus Pharmaceuticals Usa Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Zydus Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP May 2, 2022


11. ACCORD HLTHCARE

Accord Healthcare Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Discontinued INTRAVENOUS, SUBCUTANEOUS N/A Jul 26, 2022


12. SANDOZ

Sandoz Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Sandoz.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP Jul 26, 2022


13. FRESENIUS KABI USA

Fresenius Kabi Usa Llc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP May 2, 2022


14. SCINOPHARM TAIWAN

Scinopharm Taiwan Ltd has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Scinopharm Taiwan.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Discontinued INTRAVENOUS, SUBCUTANEOUS N/A Sep 26, 2023


15. DR REDDYS

Dr Reddys Laboratories Ltd has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Dr Reddys.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP Jul 26, 2022


16. HOSPIRA

Hospira Inc has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Hospira.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP Jul 26, 2022


17. BAXTER HLTHCARE CORP

Baxter Healthcare Corp has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Baxter Hlthcare Corp.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP May 2, 2022


18. RELIANCE LIFE SCI

Reliance Life Sciences Private Ltd has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Reliance Life Sci.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP Oct 11, 2022


19. JIANGSU HANSOH PHARM

Jiangsu Hansoh Pharmaceutical Group Co Ltd has filed for 1 generic for Bortezomib. Given below are the details of the strengths of this generic introduced by Jiangsu Hansoh Pharm.

Strength Dosage Form Availability Application Pathway TE code Launch Date
3.5MG/VIAL injectable Prescription INTRAVENOUS, SUBCUTANEOUS AP Jul 26, 2022